| Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy HA Knaus, S Berglund, H Hackl, AL Blackford, JF Zeidner, ... JCI insight 3 (21), 2018 | 149 | 2018 |
| A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure AM Zeidan, HA Knaus, TM Robinson, AMH Towlerton, EH Warren, ... Clinical Cancer Research 24 (15), 3519-3527, 2018 | 90 | 2018 |
| Immunomodulatory drugs: immune checkpoint agents in acute leukemia H A Knaus, C G Kanakry, L Luznik, I Gojo Current drug targets 18 (3), 315-331, 2017 | 55 | 2017 |
| Phase II trial of pembrolizumab after high-dose cytarabine in relapsed/refractory acute myeloid leukemia JF Zeidner, BG Vincent, A Ivanova, D Moore, KP McKinnon, AD Wilkinson, ... Blood cancer discovery 2 (6), 616, 2021 | 51 | 2021 |
| Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation … SR McCurdy, BS Iglehart, DA Batista, CD Gocke, Y Ning, HA Knaus, ... Leukemia 30 (10), 2102-2106, 2016 | 44 | 2016 |
| Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia S Rutella, J Vadakekolathu, F Mazziotta, S Reeder, TO Yau, ... The Journal of Clinical Investigation 132 (21), 2022 | 33 | 2022 |
| Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS JF Zeidner, HA Knaus, AM Zeidan, AL Blackford, R Montiel-Esparza, ... Leukemia 34 (6), 1563-1576, 2020 | 21 | 2020 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 21* | 2016 |
| Stabilization of myelodysplastic syndromes (MDS) following hypomethylating agent (HMAs) failure using the immune checkpoint inhibitor ipilimumab: a phase I trial AM Zeidan, JF Zeidner, A Duffield, HA Knaus, A Ferguson, K Sheldon, ... Blood 126 (23), 1666, 2015 | 19 | 2015 |
| Containment of a traceable COVID-19 outbreak among healthcare workers at a hematopoietic stem cell transplantation unit N Buchtele, W Rabitsch, HA Knaus, P Wohlfarth Bone Marrow Transplantation 55 (7), 1491-1492, 2020 | 10 | 2020 |
| Antigen-specific immunoadsorption with the Glycosorb® ABO immunoadsorption system as a novel treatment modality in pure red cell aplasia following major and bidirectional ABO … A Handisurya, N Worel, W Rabitsch, M Bojic, S Pajenda, ... Frontiers in Medicine 7, 2020 | 7 | 2020 |
| Autologous hematopoietic stem cell transplantation with concomitant SARS-CoV-2 infection HA Knaus, W Rabitsch, N Buchtele, J Cserna, P Wohlfarth Annals of Hematology, 1-4, 2021 | 6 | 2021 |
| Immune checkpoint inhibitors in aml-a new frontier R Thummalapalli, HA Knaus, I Gojo, JF Zeidner Current cancer drug targets 20 (7), 545-557, 2020 | 6 | 2020 |
| SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells G Brunhofer-Bolzer, T Le, N Dyckmanns, HA Knaus, C Pausz, P Freund, ... Journal of Medicinal Chemistry 58 (3), 1244-1253, 2015 | 6 | 2015 |
| Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight HA Knaus, S Berglund, H Hackl, AL Blackford, JF Zeidner, ... | 5 | 2018 |
| Cytokine release syndrome during antithymocyte globulin/anti-T lymphocyte globulin serotherapy for graft-versus-host disease prophylaxis before allogeneic hematopoietic stem … HA Knaus, T Rottner, CK Baumann, J Cserna, M Mitterbauer, ... Transplantation and Cellular Therapy 28 (5), 260. e1-260. e9, 2022 | 3 | 2022 |
| Acute myeloid leukemia (AML) blasts influence the gene expression signature and Co-signaling receptor expression of CD8+ T cells HA Knaus, S Berglund, H Hackl, R Montiel-Esparza, MJ Levis, JE Karp, ... Blood 128 (22), 1700, 2016 | 3 | 2016 |
| Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease J Strobl, LM Gail, L Krecu, S Madad, L Kleissl, L Unterluggauer, A Redl, ... British Journal of Dermatology 190 (3), 402-414, 2024 | 2 | 2024 |
| Epigenetic regulation of T cell lineages in skin and blood following hematopoietic stem cell transplantation RV Pandey, J Strobl, A Redl, L Unterluggauer, L Gail, L Kleissl, S Müller, ... Clinical Immunology 248, 109245, 2023 | 2 | 2023 |
| CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma N Buchtele, P Wohlfarth, T Staudinger, P Schellongowski, L Traby, ... Annals of Hematology 102 (1), 231-234, 2023 | 2 | 2023 |
Leo LuznikProfessor of Oncology, Johns Hopkins University School of MedicineVerified email at jhmi.edu
